RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88-101
Eur J Cancer
.
2018 May:94:216-217.
doi: 10.1016/j.ejca.2018.01.115.
Epub 2018 Mar 21.
Authors
Christopher J D Wallis
1
,
Zachary Klaassen
2
Affiliations
1
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. Electronic address: wallis.cjd@gmail.com.
2
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
PMID:
29573942
DOI:
10.1016/j.ejca.2018.01.115
No abstract available
Publication types
Letter
Comment
MeSH terms
Androstenes*
Humans
Male
Prostatic Neoplasms*
Substances
Androstenes
abiraterone